To include your compound in the COVID-19 Resource Center, submit it here.

FDA takes next step in new drug reorganization, including revamping oncology review

FDA announced the establishment of three new offices as part of a wide-ranging reorganization of the Center for Drug Evaluation and Review’s Office of New Drugs.

The new organization is flatter and includes new disease-focused divisions. It is intended to allow FDA to focus

Read the full 448 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers